Zimmer Biomet Holdings, Inc. (ZBH)

US — Healthcare Sector
Peers: OFIX  SRDX  LUNG  CVRX  EW  MDT  ABT  BSX  SYK  CNMD  BRKR  GKOS  BIO  SNNUF  NUVA  ITGR 

Automate Your Wheel Strategy on ZBH

With Tiblio's Option Bot, you can configure your own wheel strategy including ZBH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZBH
  • Rev/Share 37.905
  • Book/Share 68.5012
  • PB 1.3626
  • Debt/Equity 0.5158
  • CurrentRatio 3.2981
  • ROIC 0.0424

 

  • MktCap 18467132320.0
  • FreeCF/Share 7.0743
  • PFCF 12.853
  • PE 25.9157
  • Debt/Assets 0.3235
  • DivYield 0.0103
  • ROE 0.0568

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade ZBH JP Morgan Neutral Overweight $125 $128 Dec. 17, 2024
Initiation ZBH Wolfe Research -- Peer Perform -- -- Sept. 10, 2024

News

We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
ZBH
Published: May 20, 2025 by: CNBC Television
Sentiment: Neutral

Ivan Tornos, Zimmer Biomet CEO, joins 'Closing Bell Overtime' from the CNBC CEO Council Summit to talk navigating a changing political landscape, partnering with Arnold Schwarzenegger and more.

Read More
image for news We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
ABT, MDLZ, MO, NWN, ZBH
Published: May 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral

If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.

Read More
image for news Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
ZBH
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Read More
image for news ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results
ZBH
Published: May 06, 2025 by: Benzinga
Sentiment: Neutral

Zimmer Biomet Holdings, Inc ZBH reported better-than-expected earnings for the first quarter on Monday.

Read More
image for news These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results
Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds
ZBH
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and competition. Zimmer Biomet's cash flows appear set to be particularly hard hit by tariffs, meaning the company's share price is likely to remain depressed until this is resolved.

Read More
image for news Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
ZBH
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative

Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.

Read More
image for news ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript
ZBH
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants David DeMartino - SVP, IR Ivan Tornos - President & CEO Suketu Upadhyay - CFO & EVP, Finance, Operations & Supply Chain Conference Call Participants Robbie Marcus - JPMorgan David Roman - Goldman Sachs Chris Pasquale - Nephron Matthew O'Brien - Piper Sandler Matthew Taylor - Jefferies Larry Biegelsen - Wells Fargo Josh Jennings - TD Cowen Travis Steed - Bank of America Joanne Wuensch - Citi Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Shagun Singh - RBC …

Read More
image for news Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript
Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
ZBH
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics
ZBH
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral

Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Read More
image for news Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics
ZBH Stock to Gain From Volume Growth Amid Rising Costs
ZBH
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Read More
image for news ZBH Stock to Gain From Volume Growth Amid Rising Costs
PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA
FNA, ZBH
Published: April 02, 2025 by: Business Wire
Sentiment: Neutral

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston.

Read More
image for news PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA
Zimmer Biomet Focuses on Innovation Amid Growing Competition
ZBH
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative

Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.

Read More
image for news Zimmer Biomet Focuses on Innovation Amid Growing Competition
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
ZBH
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Read More
image for news ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
ZBH
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative

Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.

Read More
image for news ZBH Stock Hurt by Margin Concerns and Difficult Solvency

About Zimmer Biomet Holdings, Inc. (ZBH)

  • IPO Date 2001-07-25
  • Website https://www.zimmerbiomet.com
  • Industry Medical - Devices
  • CEO Mr. Ivan Tornos
  • Employees 17000

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.